This concept was based on the following findings: (1) The 27-gene signature centered on EZH2, identified across many types of cancers, is composed of multiple therapeutic targets such as EZH2, AURKA, MELK, TTK, KIF11, and BIRC5, whose inhibitors have been developed for cancer treatment. This evidence concerns the gene MELK and cancer.